论文部分内容阅读
目的建立血清肝再生增强因子（ＡＬＲ）的酶联免疫检测方法，了解不同肝病患者血清中ＡＬＲ水平及其意义．方法利用ＡＬＲ的酶联免疫方法检测不同肝病患者外周血清中ＡＬＲ水平．结果所建立的ＡＬＲ酶联免疫方法其最低检测到的ＡＬＲ浓度为０１μｇ／Ｌ，在１０μｇ／Ｌ范围内抗体与ＡＬＲ的反应呈良好的线性关系，与ＴＧＦα，ＥＧＦ等其他促肝细胞增殖因子无任何交叉反应．重型肝炎患者血清中ＡＬＲ水平最高（２１４μｇ／Ｌ±２１０μｇ／Ｌ），急性肝炎次之（１１２μｇ／Ｌ±０４８μｇ／Ｌ），两者均非常显著高于正常人（０３３μｇ／Ｌ±０２３μｇ／Ｌ），慢性肝炎（０４５μｇ／Ｌ±０１６μｇ／Ｌ），肝炎后肝硬变（０５７μｇ／Ｌ±０３６μｇ／Ｌ），原发性肝癌（０３５μｇ／Ｌ±０１４μｇ／Ｌ）和肝外疾病（０３１μｇ／Ｌ±０２１μｇ／Ｌ）患者（Ｐ＜００５和Ｐ＜００１）；慢性肝炎和肝炎后肝硬变患者血清中ＡＬＲ水平亦明显高于正常人（Ｐ＜００５）；原发性肝癌和肝外疾病患者血清ＡＬＲ水平与正常人无明显差异（Ｐ＞００５）．结论ＡＬＲ酶联免疫检测方法对于不同肝病患者血清中ＡＬＲ的检测具有良好的特异性和敏感性；肝病患者血清ＡＬ?
Objective To establish an enzyme - linked immunosorbent assay (ELISA) for the detection of serum augmenter of liver regeneration (ALR) and to understand the significance of serum ALR in patients with different liver diseases. Methods ALR enzyme-linked immunosorbent assay was used to detect ALR levels in peripheral blood of patients with different liver diseases. Results The lowest concentration of ALR detected by ALR enzyme-linked immunosorbent assay was 01μg / L. There was a good linear relationship between the antibody and ALR in the range of 10μg / L, Cell proliferation factor without any cross-reaction. Serum levels of ALR in patients with severe hepatitis were the highest (2.14μg / L ± 210μg / L) and acute hepatitis (12μg / L ± 0.48μg / L), both of which were significantly higher than those of normal subjects 033μg / L ± 023μg / L), chronic hepatitis (045μg / L ± 016μg / L), posthepatitic cirrhosis (057μg / L ± 036μg / L) (035μg / L ± 014μg / L) and extrahepatic disease (031μg / L ± 021μg / L) (P <005 and P <001), chronic hepatitis and Serum ALR levels in patients with posthepatitic cirrhosis were also significantly higher than those in normal controls (P <005). There was no significant difference in serum ALR levels between patients with primary liver cancer and extrahepatic diseases (P> 0.05). Conclusion ALR enzyme-linked immunosorbent assay has good specificity and sensitivity for the detection of ALR in serum of patients with different liver diseases.